CCDC137 Activators
CCDC137 Activators are a collection of chemical compounds that influence the functional activity of CCDC137 through various indirect mechanisms within cellular signaling pathways. Forskolin and IBMX, by increasing intracellular cAMP levels, indirectly lead to the activation of protein kinase A (PKA) and protein kinase G (PKG) which may phosphorylate and thus modulate proteins within CCDC137's interaction network, enhancing its function. Epigallocatechin gallate, as a tyrosine kinase inhibitor, prevents the phosphorylation of competitive signaling proteins which may liberate CCDC137 for its functional roles. Moreover, sphingosine-1-phosphate and thapsigargin activate cellular signaling that can lead to cytoskeletal rearrangements and calcium-dependent processes, respectively, potentially amplifying the role of CCDC137 in these pathways. PMA, through PKC activation, influences cytoskeletal organization, which can affect CCDC137's structural involvement in the cell.
The calcium ionophore A23187 increases intracellular calcium concentration, which can activate calcium-dependent signaling pathways, thus potentially enhancing the role of CCDC137 in the cell. Staurosporine, although a general kinase inhibitor, may indirectly foster CCDC137 activity by selectively inhibiting kinases that negatively regulate pathways where CCDC137 is functionally active, thereby facilitating an environment conducive to its activation. Collectively, these compounds, through their targeted modulation of cellular signaling, contribute to the enhancement of CCDC137's functional activity without direct interaction with the protein or upregulation of its expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP enhances CCDC137 activity by promoting PKA-mediated signaling pathways, which can phosphorylate proteins that interact with CCDC137, thus enhancing its function. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP and cGMP levels in cells. The subsequent activation of PKA and PKG may indirectly enhance CCDC137 activity through phosphorylation of proteins within its interaction network. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate is a tyrosine kinase inhibitor. By inhibiting competitive tyrosine kinase signaling, it can indirectly enhance CCDC137 activity by reducing the phosphorylation of proteins that may sequester CCDC137 or regulate its function. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate activates sphingosine-1-phosphate receptors, triggering signaling pathways that can lead to rearrangements of the cytoskeleton and influence the cellular localization and function of CCDC137. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels. This can enhance CCDC137 activity by activating calcium-dependent signaling pathways that CCDC137 is involved in. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator which can modulate signaling pathways related to cytoskeletal organization. Enhanced PKC activity could lead to changes in the cellular framework affecting CCDC137's structural role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can enhance CCDC137 activity indirectly by altering downstream signaling pathways, such as AKT signaling, which may interact with CCDC137-associated pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002, which can indirectly enhance CCDC137 activity by modulating AKT signaling and affecting the cellular processes in which CCDC137 is involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it can shift the balance of cellular signaling towards pathways that enhance CCDC137 activity, particularly those related to stress response and cytoskeletal dynamics. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK1/2 inhibitor, which may enhance CCDC137 activity by reducing ERK pathway signaling and potentially increasing the activity of pathways that CCDC137 is involved in. | ||||||